| 8:00 -
9:00 |
Check-in and breakfast |
9:00 -
10:00
|
Antibacterial Drug
Discovery in the 21st Century: Is There
Any Hope? |
Steve Projan, Wyeth Research, Cambridge,
MA |
10:00 -10:30
|
Structure Guided
Target Evaluation for Antibacterial Drug
Discovery |
Sushmita Lahiri, AstraZeneca
Pharmaceuticals, Waltham, MA |
| 10:30 -
11:00 |
Break |
| 11:00 -
11:30 |
Riboswitches |
Ken Blount |
11:30
-12:00
|
Ribosome talk, TBA |
Rib-X Pharmaceuticals, TBA |
| 12:00 -
1:00 |
Lunch |
1:00 - 2:00
|
Structural Biology
and an Effective HIV-1 Vaccine |
Peter Kwong, Vaccine Research Center,
NIH, Bethesda, MD |
2:00 - 3:00
|
Reducing Risk in Drug
Discovery, Preclinical Development of the
Hepatitis C Virus Protease Inhibitor
Telaprevir (VX-950) |
Ann Kwong, Vertex Pharmaceuticals,
Cambridge, MA |
| 3:00 - 3:30 |
Break |
3:30 - 4:00
|
Biophysical
Approaches to Target-Based Discovery of
Novel Antibacterials |
Gunther Kern, AstraZeneca
Pharmaceuticals, Waltham, MA |
4:00 - 5:00
|
Mining the Magic
Mountain for Novel Inhibitors of
Menaquinone and Fatty Acid Biosynthesis in
Mycobacterium Tuberculosis: Slow Onset
Inhibition and In Vivo Activity |
Peter Tonge, Institute for Chemical
Biology and Drug Discovery, SUNY Stony
Brook, NY |
| 5:00 -
7:00 |
Mixer |
